通化东宝(600867.SH)发预盈，预计2025年归母净利润约12.42亿元，扭亏为盈

Core Viewpoint - Tonghua Dongbao (600867.SH) is expected to achieve a net profit of approximately 1.242 billion yuan attributable to the parent company in 2025, marking a turnaround from losses in the previous year [1] Domestic Market Performance - The company is leveraging its competitive advantage from the insulin procurement bid to rapidly increase the market share of insulin analog products such as Aspart and Glargine [1] - Sales revenue in the domestic market has significantly increased compared to the previous period, driven by strong growth in multiple product categories, including Liraglutide injection and Empagliflozin tablets [1]